Exelixis Valuation
| EXEL Stock | USD 43.14 0.20 0.47% |
At this time, the firm appears to be undervalued. Exelixis shows a prevailing Real Value of $45.09 per share. The current price of the firm is $43.14. Our model computes the value of Exelixis from reviewing the firm fundamentals such as Shares Outstanding of 268.11 M, current valuation of 10.63 B, and Profit Margin of 0.30 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Exelixis' valuation include:
Price Book 5.3282 | Enterprise Value | Enterprise Value Ebitda 11.9868 | Price Sales 5.0518 | Forward PE 13.8504 |
Undervalued
Today
Please note that Exelixis' price fluctuation is very steady at this time. Calculation of the real value of Exelixis is based on 3 months time horizon. Increasing Exelixis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Exelixis stock is determined by what a typical buyer is willing to pay for full or partial control of Exelixis. Since Exelixis is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Exelixis Stock. However, Exelixis' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 43.14 | Real 45.09 | Target 46.72 | Hype 43.2 |
The intrinsic value of Exelixis' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Exelixis' stock price.
Estimating the potential upside or downside of Exelixis helps investors to forecast how Exelixis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Exelixis more accurately as focusing exclusively on Exelixis' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Exelixis' intrinsic value based on its ongoing forecasts of Exelixis' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Exelixis' closest peers.
Exelixis Cash |
|
Exelixis Revenue by Product
Exelixis Total Value Analysis
Exelixis is currently forecasted to have valuation of 10.63 B with market capitalization of 11.56 B, debt of 173.04 M, and cash on hands of 1.53 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Exelixis fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.63 B | 11.56 B | 173.04 M | 1.53 B |
Exelixis Investor Information
About 97.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.27. Exelixis had not issued any dividends in recent years. Based on the key indicators related to Exelixis' liquidity, profitability, solvency, and operating efficiency, Exelixis is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Exelixis Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Exelixis has an asset utilization ratio of 81.57 percent. This suggests that the Company is making $0.82 for each dollar of assets. An increasing asset utilization means that Exelixis is more efficient with each dollar of assets it utilizes for everyday operations.Exelixis Profitability Analysis
Based on Exelixis' profitability indicators, Exelixis may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Exelixis' ability to earn profits and add value for shareholders.Net Income | First Reported 1999-12-31 | Previous Quarter 193.6 M | Current Value 244.5 M | Quarterly Volatility 75.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.14 | 0.9604 |
|
|
For Exelixis profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Exelixis to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Exelixis utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Exelixis's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Exelixis over time as well as its relative position and ranking within its peers.
Exelixis Earnings per Share Projection vs Actual
The next projected EPS of Exelixis is estimated to be 0.833 with future projections ranging from a low of 0.78 to a high of 0.89. Exelixis' most recent 12-month trailing earnings per share (EPS TTM) is at 2.78. Please be aware that the consensus of earnings estimates for Exelixis is based on EPS before non-recurring items and includes expenses related to employee stock options.Exelixis Earnings Estimation Breakdown
The calculation of Exelixis' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Exelixis is estimated to be 0.833 with the future projection ranging from a low of 0.78 to a high of 0.89. Please be aware that this consensus of annual earnings estimates for Exelixis is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.78 Lowest | Expected EPS | 0.89 Highest |
Exelixis Earnings Projection Consensus
Suppose the current estimates of Exelixis' value are higher than the current market price of the Exelixis stock. In this case, investors may conclude that Exelixis is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Exelixis' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 19 | 76.18% | 0.0 | 0.833 | 2.78 |
Exelixis Ownership Allocation
Exelixis holds a total of 268.11 Million outstanding shares. The majority of Exelixis outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Exelixis to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Exelixis. Please pay attention to any change in the institutional holdings of Exelixis as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Exelixis Profitability Analysis
The company reported the previous year's revenue of 2.32 B. Net Income was 782.57 M with profit before overhead, payroll, taxes, and interest of 2.21 B.About Exelixis Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Exelixis. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Exelixis based exclusively on its fundamental and basic technical indicators. By analyzing Exelixis's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Exelixis's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Exelixis. We calculate exposure to Exelixis's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Exelixis's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.2 B | 2.3 B | |
| Pretax Profit Margin | 0.41 | 0.14 | |
| Operating Profit Margin | 0.38 | 0.09 | |
| Net Profit Margin | 0.34 | 0.11 | |
| Gross Profit Margin | 0.96 | 1.14 |
Exelixis Growth Indicators
Investing in growth stocks can be very risky. If the company such as Exelixis does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 281.9 M | |
| Quarterly Earnings Growth Y O Y | 0.725 | |
| Forward Price Earnings | 13.8504 |
Exelixis Current Valuation Indicators
Exelixis' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Exelixis' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Exelixis, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Exelixis' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Exelixis' worth.When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.725 | Earnings Share 2.78 | Revenue Per Share | Quarterly Revenue Growth 0.108 | Return On Assets |
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.